- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07521007
Um Ensaio Clínico de Fase 2b do YN001 em Adultos com Aterosclerose Coronária (PURIFY-TIMI 81)
Um Ensaio Clínico Randomizado, Multicêntrico, Duplo-cego, Paralelo, Controlado por Placebo de Fase 2b para Avaliar a Eficácia e Segurança do YN001 em Adultos com Aterosclerose Coronária
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Jingmei Zhang, Master
- Número de telefone: 0086 010 82599080
- E-mail: zhangjingmei@innovmedicine.com
Estude backup de contato
- Nome: Kaiqi Zong, Master
- Número de telefone: 0086 010 82599080
- E-mail: zongkaiqi@innovmedicine.com
Locais de estudo
-
-
New South Wales
-
Penrith, New South Wales, Austrália, 2750
- Recrutamento
- Cannopy Clinical Research
-
Contato:
- Karen Kaluhin, MD
- Número de telefone: 0061 0491 276 512
- E-mail: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Austrália, 4064
- Recrutamento
- Core Research Group Pty Ltd.
-
Contato:
- David Colquhou, MD
- Número de telefone: 614-1184-2788
- E-mail: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Austrália, 3025
- Recrutamento
- Canopy Clinical Research
-
Contato:
- Oscar Walsh, MD
- Número de telefone: 0061 03 9968 7601
- E-mail: owalsh@canopycr.com.au
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R2H 2A6
- Ainda não está recrutando
- St. Boniface Hospital
-
Contato:
- Shuangbo Liu
- Número de telefone: 204-237-2793
- E-mail: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Canadá, N5A 5A5
- Ainda não está recrutando
- London Health Sciences Centre
-
Contato:
- Habib Khan
- Número de telefone: 519-663-3197
- E-mail: habib.khan@lhsc.on.ca
-
North York, Ontario, Canadá, M6B 3H7
- Ainda não está recrutando
- North York Diagnostic and Cardiac Centre
-
Contato:
- Subodh Verma, MD
- Número de telefone: 416-436-0244
- E-mail: subodh.verma@unityhealth.to
-
Toronto, Ontario, Canadá, M5B 1W8
- Ainda não está recrutando
- St. Michael's Hospital
-
Contato:
- John Graham
- Número de telefone: 416-864-6060
- E-mail: John.Graham@unityhealth.to
-
Vaughan, Ontario, Canadá, L6A 4N9
- Ainda não está recrutando
- Cardiac Clinic
-
Contato:
- Navneet Singh
- Número de telefone: 905-417-3001
- E-mail: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Canadá, M5G 2N2
- Ainda não está recrutando
- Toronto General Hospital - University Health Network
-
Contato:
- Jacob Udell
- Número de telefone: 416-340-4800
- E-mail: jay.udell@utoronto.ca
-
-
-
-
An
-
Hefei, An, China, 230022
- Recrutamento
- The First Affiliated Hospital of Anhui Medical Unversity
-
Contato:
- Jianlong Wang, MD
- Número de telefone: 0086-13681292304
- E-mail: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Recrutamento
- Anhui Provincial Hospital
-
Contato:
- Kangyu Chen, MD
- Número de telefone: 0086 18056005099
- E-mail: ustccky@126.com
-
Investigador principal:
- Kangyu Chen, MD
-
Subinvestigador:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100035
- Recrutamento
- Beijing Jishuitan Hospital
-
Investigador principal:
- Wei Liu, MD
-
Contato:
- Qingwei Ji, MD
- Número de telefone: 0086 18376642655
- E-mail: jqwl24@163.cou
-
Investigador principal:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, China, 100029
- Recrutamento
- Anzhen Hospital
-
Contato:
- Yuyang Liu, MD
- Número de telefone: 0086 010-64456488
- E-mail: liuyy803803@163.com
-
Investigador principal:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, China, 101100
- Ainda não está recrutando
- Beijing Luhe Hospital
-
Contato:
- Guangyao Zhai, MD
- Número de telefone: +86 1069543901
- E-mail: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Recrutamento
- Fujian Medical University Union Hospital
-
Contato:
- Mingfang Ye, MD
- Número de telefone: 0086 13960818759
- E-mail: xieheyemingfang@163.com
-
Investigador principal:
- Mingfang Ye, MD
-
Subinvestigador:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- Recrutamento
- The Second Hospital & Clinical Medical School Lanzhou University
-
Contato:
- Feng Bai, MD
- Número de telefone: 0086-13609363049
- E-mail: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recrutamento
- Guangdong Provincial People's Hospital
-
Contato:
- Ning Tan, MD
- E-mail: tanning100@126.com
-
Contato:
- Número de telefone: 0086-13903073651
- E-mail: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, China, 163316
- Recrutamento
- Daqing People's Hospital
-
Contato:
- Shu Zhang
- Número de telefone: +86-459-6612898
- E-mail: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, China, 150001
- Recrutamento
- The First Affiliated Hospital of Harbin Medical University
-
Contato:
- Lu Fu, MD
- Número de telefone: 0086 137 9668 4968
- E-mail: fuluyidayi@163.com
-
Investigador principal:
- Lu Fu, MD
-
Investigador principal:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Recrutamento
- Zhongnan Hospital of Wuhan University
-
Contato:
- Xiaorong Hu, MD
- Número de telefone: 0086 15927681634
- E-mail: huzrzn@whu.edu.cn
-
Investigador principal:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recrutamento
- The Second Xiangya Hospital fo Central South University
-
Contato:
- Xinqun Hu, MD
- Número de telefone: 0086-13307313627
- E-mail: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, China, 130033
- Recrutamento
- The First Hospital of Jilin University
-
Investigador principal:
- Qian Tong, MD
-
Contato:
- Qian Tong, MD
- Número de telefone: 0086 13074337289
- E-mail: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110015
- Recrutamento
- The People's Hospital of Liaoning Province
-
Investigador principal:
- Ying Liu, MD
-
Contato:
- Ying Liu, MD
- Número de telefone: 0086 13840065379
- E-mail: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710068
- Recrutamento
- Shaanxi Provincial People's Hospital
-
Contato:
- Xiling Shou, MD
- Número de telefone: 0086 18966700335
- E-mail: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, China
- Recrutamento
- Central Hospital Affiliated to Shandong First Medicial University
-
Contato:
- Guohai Su, MD
- Número de telefone: 0086 19953193319
- E-mail: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Recrutamento
- Fudan University-Zhongshan Hospital
-
Investigador principal:
- Junbo Ge, MD
-
Contato:
- Junbo Ge, MD
- Número de telefone: 021-64041990
- E-mail: ge.junbo@zs-hospital.sh.cn
-
Subinvestigador:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, China, 200001
- Recrutamento
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Contato:
- Jun Bu, MD
- Número de telefone: 0086 13601958108
- E-mail: pujun310@hotmail.com
-
Investigador principal:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recrutamento
- West China Hospital of Sichuan University
-
Contato:
- Yong He, MD
- Número de telefone: 0086 18980602038
- E-mail: zznnyeah@163.com
-
Investigador principal:
- Yong He, MD
-
Chengdu, Sichuan, China, 610072
- Recrutamento
- Sichuan Provincial People's Hospital
-
Contato:
- Jianhong Tao, DM
- Número de telefone: 86-189 8183 8875
- E-mail: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300211
- Recrutamento
- The Second Hospital of Tianjin Medical University
-
Contato:
- Tong Liu, MD
- Número de telefone: 0086 13902183163
- E-mail: liutongdoc@126.com
-
Investigador principal:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, China, 300121
- Recrutamento
- Tianjin People's Hospital
-
Investigador principal:
- Zhuhua Yao, MD
-
Contato:
- Zhuhua Yao, MD
- Número de telefone: 0086 13902199877
- E-mail: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Recrutamento
- Zhejiang Provincial People's Hospital
-
Contato:
- Lihong Wang, MD
- Número de telefone: 0086-13666690598
- E-mail: wlhhz@hotmail.com
-
Suzhou, Zhejiang, China, 215006
- Recrutamento
- The First Affiliated Hospital of Soochow University
-
Contato:
- Tingbo Jiang, MD
- Número de telefone: 0086-18906201122
- E-mail: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, China, 325000
- Recrutamento
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Contato:
- lianpin Wu, MD
- E-mail: 198019@wzhealth.com
-
-
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801-4312
- Recrutamento
- Heart Center Research, LLC
-
Contato:
- Walter Haught, MD
- Número de telefone: 256-519-8472
- E-mail: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Estados Unidos, 91740
- Ainda não está recrutando
- Thrive Clinical Research Group, LLC
-
Contato:
- Sami Hayek
- Número de telefone: 818-280-4220
- E-mail: samihayek82@hotmail.com
-
Contato:
- E-mail: shayek@foothillcardiology.com
-
Lincoln, California, Estados Unidos, 95648
- Ainda não está recrutando
- Clinical Trials Research
-
Contato:
- Jeffrey Wayne, MD
- Número de telefone: 916-434-8230
- E-mail: jwaynemd@ctrsites.com
-
Los Alamitos, California, Estados Unidos, 90720
- Ainda não está recrutando
- University of California Irvine Medical Center - Cardiovascular Center
-
Contato:
- Arnold Seto
- Número de telefone: 562-598-3200
- E-mail: arnold.seto@va.gov
-
Stanford, California, Estados Unidos, 94305-2200
- Ainda não está recrutando
- Stanford Health Care General Cardiology
-
Contato:
- Fahim Abbasi, MD
- Número de telefone: 650-723-6459
- E-mail: fahim@stanford.edu
-
Torrance, California, Estados Unidos, 90502-2006
- Recrutamento
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Contato:
- Matthew Budoff, MD
- Número de telefone: 310-222-3641
- E-mail: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33434
- Ainda não está recrutando
- Flourish Research - Boca Raton
-
Contato:
- Richard Goldman
- Número de telefone: 561-756-8206
- E-mail: rgoldman@flourishresearch.com
-
Hialeah, Florida, Estados Unidos, 33016-1895
- Recrutamento
- New Generation of Medical Research, LLC.
-
Contato:
- Karelia Ruiz
- Número de telefone: 305-828-9100
- E-mail: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Estados Unidos, 33709
- Recrutamento
- HCA Florida Heart Institute
-
Contato:
- Robert Sanchez, MD
- Número de telefone: 727-490-2100
- E-mail: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30303-3049
- Ainda não está recrutando
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Contato:
- Modele Ogunniyi
- Número de telefone: 404-616-4440
- E-mail: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Estados Unidos, 83642
- Ainda não está recrutando
- St. Luke's Clinic - Idaho Cardiology Associates
-
Contato:
- Brian Nolan
- Número de telefone: 208-322-1680
- E-mail: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Estados Unidos, 62781
- Ainda não está recrutando
- Southern Illinois University School of Medicine
-
Contato:
- Abdul Hafiz, MD
- Número de telefone: 217-545-8000
- E-mail: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66211-1215
- Recrutamento
- Midwest Heart & Vascular Specialists, LLC
-
Contato:
- Stephen Bloom, MD
- Número de telefone: 913-253-3000
- E-mail: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110-1032
- Recrutamento
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Contato:
- Farhan Katchi, MD
- Número de telefone: 314-362-1291
- E-mail: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos, 27607
- Ainda não está recrutando
- NC Heart and Vascular Research, LLC
-
Contato:
- Mohit Pasi
- Número de telefone: 919-784-2300
- E-mail: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Estados Unidos, 27104-3520
- Ainda não está recrutando
- Javara Inc. - Wake Forest University Health Sciences
-
Contato:
- Michael Shapiro, MD
- Número de telefone: 336-713-7251
- E-mail: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Ainda não está recrutando
- The Christ Hospital
-
Contato:
- Mark Berlacher, MD
- Número de telefone: 513-585-1777
- E-mail: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73135
- Ainda não está recrutando
- South Oklahoma Heart Research, LLC
-
Contato:
- Naeem Tahirkheli
- Número de telefone: 405-628-6865
- E-mail: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Estados Unidos, 17011
- Recrutamento
- Capital Area Research, LLC - Camp Hill
-
Contato:
- Venkatesh Nadar, MD
- Número de telefone: 717-695-8722
- E-mail: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79106
- Recrutamento
- PharmaTex Research, LLC
-
Contato:
- David Brabham
- Número de telefone: 806-355-2581
- E-mail: dgbrabham@hotmail.com
-
Carrollton, Texas, Estados Unidos, 75010
- Ainda não está recrutando
- Pulse Care Heart and Vascular
-
Contato:
- Kiran Kumar Mangalpally
- Número de telefone: 214-407-8640
- E-mail: trials@stryderesearch.com
-
Tomball, Texas, Estados Unidos, 77375
- Ainda não está recrutando
- DM Clinical Research - Dallas
-
Contato:
- Mustafa Mandviwala
- Número de telefone: 346-550-9559
- E-mail: drmandviwala.ns@dmclinical.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Experimental: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Comparador de Placebo: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Prazo: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Prazo: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Prazo: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Prazo: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Prazo: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Prazo: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Prazo: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Prazo: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Prazo: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Prazo: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Prazo: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Prazo: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Prazo: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Prazo: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- YN001-203
- IND 157167 (Identificador de registro: Beijing Inno Medicine Co., Ltd.)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .